BioNTech (NASDAQ:BNTX) Shares Down 6.5% - What's Next?

Key Points

• BioNTech's stock price fell 6.5% on Monday, reaching a low of $103.80 before recovering slightly to close at $105.17, with trading volume down 38% from the average.
• Despite the recent drop, several analysts maintain a positive outlook, with an average price target of $135.80 and a consensus rating of "Moderate Buy."
• In its latest earnings report, BioNTech reported a revenue of $306.46 million, significantly exceeding estimates, but posted a loss of ($1.60) EPS that missed expectations by $0.19.

BioNTech SE Sponsored ADR (NASDAQ:BNTX - Get Free Report)'s share price fell 6.5% on Monday . The stock traded as low as $103.80 and last traded at $105.17. 576,851 shares traded hands during trading, a decline of 38% from the average session volume of 928,656 shares. The stock had previously closed at $112.46.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on BNTX shares. Morgan Stanley upped their price target on shares of BioNTech from $132.00 to $133.00 and gave the company an "overweight" rating in a research note on Thursday, July 10th. Truist Financial reaffirmed a "buy" rating and set a $155.00 price target (up previously from $151.00) on shares of BioNTech in a report on Tuesday, June 3rd. HC Wainwright reissued a "buy" rating and issued a $136.00 price objective on shares of BioNTech in a research note on Monday. The Goldman Sachs Group started coverage on shares of BioNTech in a research report on Thursday, May 29th. They set a "neutral" rating and a $110.00 price objective for the company. Finally, Bank of America increased their target price on shares of BioNTech from $126.00 to $134.00 and gave the stock a "buy" rating in a research note on Tuesday, August 5th. Thirteen investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, BioNTech presently has a consensus rating of "Moderate Buy" and an average price target of $135.80.

BioNTech Stock Down 8.5%

The business has a fifty day simple moving average of $109.49 and a two-hundred day simple moving average of $104.33. The company has a quick ratio of 8.48, a current ratio of 8.61 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $24.74 billion, a price-to-earnings ratio of -64.44 and a beta of 1.39.

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its earnings results on Monday, August 4th. The company reported ($1.60) EPS for the quarter, missing the consensus estimate of ($1.41) by ($0.19). The business had revenue of $306.46 million for the quarter, compared to the consensus estimate of $161.26 million. BioNTech had a negative net margin of 12.20% and a negative return on equity of 1.84%. The business's revenue was up 102.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($3.36) EPS. BioNTech has set its FY 2025 guidance at EPS. Equities analysts expect that BioNTech SE Sponsored ADR will post -3.88 EPS for the current year.

Hedge Funds Weigh In On BioNTech

Several large investors have recently added to or reduced their stakes in BNTX. Banque Cantonale Vaudoise bought a new stake in shares of BioNTech during the 1st quarter worth $36,000. LRI Investments LLC increased its holdings in BioNTech by 234.6% during the second quarter. LRI Investments LLC now owns 445 shares of the company's stock valued at $47,000 after buying an additional 312 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in shares of BioNTech by 118.2% during the second quarter. Tower Research Capital LLC TRC now owns 563 shares of the company's stock worth $60,000 after acquiring an additional 305 shares during the last quarter. Hantz Financial Services Inc. lifted its holdings in shares of BioNTech by 472.0% in the 2nd quarter. Hantz Financial Services Inc. now owns 572 shares of the company's stock worth $61,000 after acquiring an additional 472 shares during the last quarter. Finally, Banque Transatlantique SA purchased a new position in BioNTech in the 1st quarter worth about $80,000. Institutional investors own 15.52% of the company's stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.